MedTrace Logo

Clinical Research on the Use of Immune Checkpoint Inhibitors Combined With Chidamide for the Functional Cure of AIDS

NCT06902038 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2025-03-30

No results posted yet for this study

Summary

Evaluate the efficacy and safety of immune checkpoint inhibitors combined with chidamide as an "activate and kill" strategy to extend viral rebound time, reduce the HIV reservoir, and achieve functional cure.

Conditions

  • HIV-1 Infection

Interventions

DRUG

PD-1 inhibitor

100mg of sindilizumab, was dissolved into 50ml of normal saline q3w ×2

DRUG

Sidarbenamide

Sidarbenamide 10mg biw orally for 2 weeks

DRUG

Saline (NaCl 0,9 %) (placebo)

Saline 50ml Q3W ×2

Sponsors & Collaborators

  • Jun Chen, MD

    lead OTHER_GOV

Principal Investigators

  • Jun Chen, MD · Shanghai Public Health Clinical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-22
Primary Completion
2025-12-01
Completion
2027-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06902038 on ClinicalTrials.gov